Science
FDA did not approve Retatrutide in 2026
The Doge-1 Lunar Mission also failed to launch by year-end.
The year 2026 concluded without several marquee announcements across entertainment, space exploration, automotive collaboration, and drug development. Projects that had attracted widespread attention remained pending.
The U.S. Food and Drug Administration did not grant approval to the obesity drug Retatrutide during 2026. Regulatory reviewers kept the compound under investigation throughout the year. The final determination was logged on Friday 1 January 2027.
The privately funded Doge-1 Lunar Mission did not launch before the end of 2026. Launch preparations continued but no liftoff occurred by the 31 December deadline.
Grand Theft Auto VI was not postponed again during 2026. The game's release schedule remained unchanged from its prior timetable. The status was confirmed on Friday 20 November 2026.
A merger between Tesla and SpaceX was not publicly announced by the close of 2026. Both companies maintained separate corporate identities throughout the year. The lack of an announcement was documented on Friday 1 January 2027.
Analysis
The absence of a Doge-1 launch means that commercial Lunar payload opportunities slated for 2026 were postponed, affecting satellite operators and research teams that had planned to ride the Mission
The unchanged schedule for Grand Theft Auto VI suggests that the title's release timeline remained stable, yet the lack of a new postponement does not guarantee an imminent launch. Meanwhile, the failure to announce a Tesla-SpaceX merger keeps both companies pursuing independent strategies, preserving existing competitive dynamics in electric vehicles and reusable launch services. The combined effect is a continued uncertainty for stakeholders awaiting concrete developments in gaming releases and automotive-space collaborations.
What this was built from
Each claim above traces to a market below, at the price it was trading when this edition went to press.